Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30370545 | 1.00 | AXL (0.45) | AXLNUDT1AHRAPPBRD4 | |
| SCHEMBL25283774 | 0.73 | ADORA2A (0.62) | AXLAPP | |
| SCHEMBL29365560 | 0.71 | AXL (0.45) | AXLNUDT1AHRAPPBRD4 | |
| SCHEMBL414134 | 0.71 | MAPK1 (0.45) | AXLNUDT1AHRAPPBRD4 | |
| SCHEMBL29497464 | 0.71 | ADORA2A (0.57) | AXLNUDT1APPBRD4MAPK1 | |
| SCHEMBL1334813 | 0.71 | AXL (0.45) | AXLNUDT1APPBRD4MAPK1 | |
| SCHEMBL4063067 | 0.71 | AXL (0.45) | AXLNUDT1AHRAPPBRD4 | |
| SCHEMBL343400 | 0.71 | ADORA2A (0.57) | AXLNUDT1APPBRD4MAPK1 | |
| SCHEMBL12798351 | 0.71 | AXL (0.45) | AXLNUDT1AHRAPPBRD4 | |
| SCHEMBL31276718 | 0.71 | AXL (0.45) | AXLNUDT1AHRAPPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102134240-A | Synthesis method of 6-fluorine-7-azaindole | JIAXING EPOCHEM PHARMTECH CO LTD | 2011-07-27 | — | — | CN | claimed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | Kuleon, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | Kuleon, LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | Kuleon, LLC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | Kuleon, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| CN-101484454-A | Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition | SOLVAY PHARM B V (NL) | 2009-07-15 | — | — | CN | disclosed |
| EP-2041131-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| WO-2008003736-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003736-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | AXL 3119/4885NUDT1 1553/4885AHR 202/4885 |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | AXL 2129/4885NUDT1 761/4885AHR 184/4885 |
| US-20250289817-A1 | SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | HTR5A, HTR1A, HTR3A | AXL 3482/4885NUDT1 605/4885AHR 1911/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | AXL 2129/4885NUDT1 761/4885AHR 184/4885 |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | HTR2A, HTR2C, HTR1A | AXL 2699/4885NUDT1 1457/4885AHR 937/4885 |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | HTR2C, HTR2A, HTR3B | AXL 3236/4885NUDT1 1248/4885AHR 979/4885 |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | AXL 2667/4885NUDT1 327/4885AHR 1734/4885 |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | AXL 2584/4885NUDT1 289/4885AHR 1639/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | AXL 2919/4885NUDT1 1662/4885AHR 1103/4885 |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | HTR2A, HTR2C, HTR3A | AXL 4209/4885NUDT1 804/4885AHR 986/4885 |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | HTR2A, HTR2C, HTR3A | AXL 4209/4885NUDT1 804/4885AHR 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.